Research Analysts Offer Predictions for OBIO FY2025 Earnings

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Research analysts at HC Wainwright cut their FY2025 EPS estimates for Orchestra BioMed in a research note issued on Thursday, November 13th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($1.73) per share for the year, down from their previous forecast of ($1.67). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Orchestra BioMed’s Q4 2025 earnings at ($0.38) EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.63) EPS.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $0.74 million. Orchestra BioMed had a negative net margin of 2,665.05% and a negative return on equity of 320.09%.

A number of other equities analysts have also recently issued reports on OBIO. BTIG Research reaffirmed a “neutral” rating on shares of Orchestra BioMed in a report on Wednesday, August 20th. Barclays lowered their price objective on Orchestra BioMed from $12.00 to $11.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Orchestra BioMed in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

Orchestra BioMed Trading Down 5.7%

Shares of Orchestra BioMed stock opened at $3.94 on Monday. The firm’s 50 day moving average is $3.21 and its 200 day moving average is $3.00. The firm has a market capitalization of $222.49 million, a PE ratio of -2.16 and a beta of 0.65. Orchestra BioMed has a 1 year low of $2.20 and a 1 year high of $6.39. The company has a current ratio of 4.73, a quick ratio of 4.72 and a debt-to-equity ratio of 0.32.

Hedge Funds Weigh In On Orchestra BioMed

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Orchestra BioMed by 28.0% in the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after acquiring an additional 324,558 shares during the period. Pathstone Holdings LLC purchased a new stake in Orchestra BioMed in the third quarter worth about $2,495,000. Knott David M Jr boosted its stake in shares of Orchestra BioMed by 95.0% during the third quarter. Knott David M Jr now owns 195,000 shares of the company’s stock valued at $484,000 after purchasing an additional 95,000 shares in the last quarter. AMH Equity Ltd purchased a new position in shares of Orchestra BioMed in the 3rd quarter valued at $412,000. Finally, IFP Advisors Inc raised its holdings in Orchestra BioMed by 106.4% in the first quarter. IFP Advisors Inc now owns 161,921 shares of the company’s stock worth $693,000 after purchasing an additional 83,481 shares in the last quarter. Institutional investors own 53.20% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.